Bladder and Urothelial Cancer Treatments

SEP 10, 2026 · JOURNAL ARTICLE

KẾT QUẢ BƯỚC ĐẦU NÚT MẠCH ĐIỀU TRỊ VIÊM BÀNG QUANG CHẢY MÁU SAU XẠ TRỊ

Tạp Chí Y Học Cộng Đồng

Single-centre case series of 15 patients with uncontrolled hemorrhagic cystitis treated with arterial embolization; real clinical outcome but uncontrolled design, no comparator, and small sample limit strength of evidence.

SEP 9, 2026 · JOURNAL ARTICLE

Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review

Human Vaccines & Immunotherapeutics

A single case report with literature review describing a rare adverse event; provides clinical observation and management guidance but lacks comparative data or controlled evidence of incidence or causality.

SEP 9, 2026 · JOURNAL ARTICLE

Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib

Frontiers in Immunology

A single case report with sustained disease response offers an anecdotal observation but lacks the controlled design, comparator, or sample size needed to establish efficacy; the authors explicitly acknowledge limited evidence requiring validation.

SEP 9, 2026 · JOURNAL ARTICLE

Health-Related Quality of Life Among People Diagnosed with High-Risk Non-Muscle Invasive Bladder: Baseline Data from the ANZUP BCG + Mitomycin Clinical Trial

Cancers

Baseline cross-sectional descriptive study from an ongoing trial, measuring associations between quality of life and symptom burden in treatment-naïve patients; provides foundational data but no intervention effect, control arm, or outcome data.

SEP 8, 2026 · JOURNAL ARTICLE

Sex, Timing, and Outcomes of Curative-Intent Immunotherapy

JAMA Network Open

Large, rigorous meta-analysis of 38 randomized phase 3 trials with 31,721 patients showing statistically significant OS and disease-free survival benefits from ICIs in curative solid tumors, with no sex difference detected, though female underrepresentation limits generalizability.

SEP 8, 2026 · JOURNAL ARTICLE

Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era

Frontiers in Immunology

A narrative review synthesizing current evidence and raising mechanistic questions about tertiary lymphoid structures in urothelial carcinoma, without new empirical data or prospective validation of proposed biomarker relationships.

SEP 7, 2026 · REVIEW

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology

A systematic review synthesizing evidence on biomarkers for BCG therapy prediction in bladder cancer; provides a landscape assessment rather than a new empirical result, identifying gaps and promising directions for clinical practice.

SEP 7, 2026 · JOURNAL ARTICLE

Adjuvant therapy and fear of cancer recurrence in bladder cancer survivors: a cross-sectional pilot study

BMC Urology

A single-centre, underpowered cross-sectional pilot study explicitly designed as hypothesis-generating, with a null primary finding that the authors acknowledge cannot rule out a clinically meaningful effect.